Dogwood Therapeutics DWTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's cash & equivalents?
- Dogwood Therapeutics (DWTX) reported cash & equivalents of $13.23M in Q1 2026.
- How has Dogwood Therapeutics's cash & equivalents changed year-over-year?
- Dogwood Therapeutics's cash & equivalents decreased by 24.6% year-over-year, from $17.54M to $13.23M.
- What is the long-term trend for Dogwood Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Dogwood Therapeutics's cash & equivalents has grown at a -26.2% compound annual growth rate (CAGR), from $29.8M to $6.52M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.